Advances in the diagnosis, treatment and management of neuroendocrine tumors have led to a consensus meeting of the National Cancer Institute, the new directions of which are now reported by Kulke and colleagues. Many thoughtful proposals are presented that should be of interest to the increasing number of physicians who see patients with these unique tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Moertel, C. G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J. Clin. Oncol. 5, 1502–1522 (1987).
Kulke, M. H. et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. J. Clin. Oncol. 29, 934–943 (2011).
Yao, J. C. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008).
Metz, D. C. & Jensen, R. T. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology 135, 1469–1492 (2008).
Modlin, I. M. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61–72 (2008).
Jensen, R. T. & Delle Fave, G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N. Engl. J. Med. 364, 564–565 (2011).
Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656–4663 (2009).
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
Kwekkeboom, D. J., de Herder, W. W. & Krenning, E. P. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 40, 173–185 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Jensen, R. A roadmap for the land of small tumors. Nat Rev Endocrinol 7, 319–321 (2011). https://doi.org/10.1038/nrendo.2011.73
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.73
